238 related articles for article (PubMed ID: 8156519)
1. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment.
Caleffi M; Teague MW; Jensen RA; Vnencak-Jones CL; Dupont WD; Parl FF
Cancer; 1994 Apr; 73(8):2147-56. PubMed ID: 8156519
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer.
Roodi N; Bailey LR; Kao WY; Verrier CS; Yee CJ; Dupont WD; Parl FF
J Natl Cancer Inst; 1995 Mar; 87(6):446-51. PubMed ID: 7861463
[TBL] [Abstract][Full Text] [Related]
5. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.
Kovach JS; Hartmann A; Blaszyk H; Cunningham J; Schaid D; Sommer SS
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1093-6. PubMed ID: 8577720
[TBL] [Abstract][Full Text] [Related]
6. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
7. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
10. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
11. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
12. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
[TBL] [Abstract][Full Text] [Related]
13. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer.
Ito I; Yoshimoto M; Iwase T; Watanabe S; Katagiri T; Harada Y; Kasumi F; Yasuda S; Mitomi T; Emi M
Br J Cancer; 1995 Mar; 71(3):438-41. PubMed ID: 7880720
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 gene alterations in node-negative breast cancer.
Elledge RM; Fuqua SA; Clark GM; Pujol P; Allred DC; McGuire WL
Breast Cancer Res Treat; 1993; 26(3):225-35. PubMed ID: 8251647
[TBL] [Abstract][Full Text] [Related]
16. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
17. p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer.
Sasa M; Kondo K; Komaki K; Morimoto T; Monden Y
J Surg Oncol; 1994 May; 56(1):46-50. PubMed ID: 8176940
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of TP53 alterations in breast carcinoma.
Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
20. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
